Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
Klisovic RB, Blum W, Wei X, Liu S, Liu Z, Xie Z, Vukosavljevic T, Kefauver C, Huynh L, Pang J, Zwiebel JA, Devine S, Byrd JC, Grever MR, Chan K, Marcucci G.
Klisovic RB, et al. Among authors: zwiebel ja.
Clin Cancer Res. 2008 Jun 15;14(12):3889-95. doi: 10.1158/1078-0432.CCR-08-0109.
Clin Cancer Res. 2008.
PMID: 18559610
Free PMC article.
Clinical Trial.